This suggests that while PI3Kα inhibition may be optimally tailored toward PIK3CA-mutated breast tumor types, PI3Kβ inhibition may be exploited for PTEN-deficient breast tumors, notably for TNBC. This evidence concerns the gene PTEN and breast neoplasm.